BRAF and non-small cell lung carcinoma: Analysis of our patient cohort revealed that concurrent BRAF and RAS mutations occur in a substantial proportion of NSCLC patients: 9.0% in Class I, 20.7% in Class II, and 21.5% in Class III (Supplementary Fig. 4e).